Nothing Special   »   [go: up one dir, main page]

MA32821B1 - Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier) - Google Patents

Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)

Info

Publication number
MA32821B1
MA32821B1 MA33877A MA33877A MA32821B1 MA 32821 B1 MA32821 B1 MA 32821B1 MA 33877 A MA33877 A MA 33877A MA 33877 A MA33877 A MA 33877A MA 32821 B1 MA32821 B1 MA 32821B1
Authority
MA
Morocco
Prior art keywords
vaccine
coqueluche
combinally
whole cellular
antigens
Prior art date
Application number
MA33877A
Other languages
Arabic (ar)
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Lavit Jambu
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA32821B1 publication Critical patent/MA32821B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN VACCIN COMBINÉ COMPRENANT UN MÉLANGE D'ANTIGÈNES POUR LA PROTECTION CONTRE DES MALADIES TELLES QUE LA DIPHTÉRIE, LE TÉTANOS, LA COQUELUCHE (VACCIN CELLULAIRE ENTIER) ET LA POLIO. LA PRÉSENTE INVENTION CONCERNE AUSSI L'INCLUSION D'UN OU DE PLUSIEURS ANTIGÈNES DANS CE VACCIN COMBINÉ, POUR LA PROTECTION CONTRE DES INFECTIONS PAR HAEMOPHILUS INFLUENZAE, LE VIRUS DE L'HÉPATITE, ET D'AUTRES PATHOGÈNES, DE SORTE QUE L'ADMINISTRATION DE CE VACCIN PUISSE SIMULTANÉMENT IMMUNISER UN SUJET CONTRE PLUS D'UN PATHOGÈNE. CETTE INVENTION EN PARTICULIER CONCERNE UN VACCIN COMBINÉ STABLE, COMPLÈTEMENT LIQUIDE, COMPRENANT LES ANTIGÈNES TELS QUE SUSMENTIONNÉS ET LES PROCÉDÉS DE FABRICATION DE CE VACCIN.
MA33877A 2008-10-24 2011-05-20 Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier) MA32821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2437DE2008 2008-10-24
PCT/IN2009/000599 WO2010046934A1 (fr) 2008-10-24 2009-10-23 Vaccin combiné notamment contre la coqueluche (vaccin cellulaire entier)

Publications (1)

Publication Number Publication Date
MA32821B1 true MA32821B1 (fr) 2011-11-01

Family

ID=42119002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33877A MA32821B1 (fr) 2008-10-24 2011-05-20 Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)

Country Status (14)

Country Link
US (1) US20110195087A1 (fr)
EP (2) EP2529750A1 (fr)
JP (1) JP2012506420A (fr)
CN (1) CN102196817B (fr)
AP (1) AP2011005700A0 (fr)
AR (1) AR073957A1 (fr)
BR (1) BRPI0920629A2 (fr)
CA (1) CA2741393A1 (fr)
CL (1) CL2011000913A1 (fr)
CO (1) CO6430435A2 (fr)
MA (1) MA32821B1 (fr)
PE (1) PE20100365A1 (fr)
RU (2) RU2504398C2 (fr)
WO (1) WO2010046934A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633898B (zh) * 2012-04-23 2013-11-27 成都欧林生物科技股份有限公司 一种Hib多糖与蛋白结合工艺的优化方法
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
BR112018005291A2 (pt) * 2015-09-16 2018-10-09 Lg Chemical Ltd composição para vacina combinada para dosagem múltipla
BR112019003419A2 (pt) * 2016-08-26 2019-05-21 Serum Institute Of India Private Limited composição de vacina multivalente
CA3070039A1 (fr) * 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. Composition immunogene a stabilite amelioree, immunogenicite amelioree et moindre reactogenicite, et procede de preparation de cette derniere
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020165920A1 (fr) * 2019-02-12 2020-08-20 Biological E Limited Composition vaccinale multivalente
WO2021176409A1 (fr) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Combinaison de conservateurs pour composition de vaccin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097140A (en) 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
US3097142A (en) 1960-03-30 1963-07-09 Merck & Co Inc Benzyl alcohol stabilized polio vaccines and production thereof
ATE168271T1 (de) * 1992-05-23 1998-08-15 Smithkline Beecham Biolog Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
DE69736709T2 (de) 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
MXPA03000198A (es) 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
GB0223355D0 (en) 2002-10-08 2002-11-13 Chiron Spa Vaccine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
KR20030069918A (ko) 2003-06-25 2003-08-27 주식회사 삼정산업 간편 조립식 파렛트 판재, 간편 조립식 파렛트 중간지지구및 간편 조립식 파렛트와 그의 제작방법
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
EA010057B1 (ru) * 2004-08-27 2008-06-30 Панацея Биотек Лтд. Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
KR20090057423A (ko) 2006-09-07 2009-06-05 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신

Also Published As

Publication number Publication date
CN102196817A (zh) 2011-09-21
CL2011000913A1 (es) 2012-01-20
RU2504398C2 (ru) 2014-01-20
CN102196817B (zh) 2016-04-06
PE20100365A1 (es) 2010-05-21
JP2012506420A (ja) 2012-03-15
CA2741393A1 (fr) 2010-04-29
EP2361094A1 (fr) 2011-08-31
CO6430435A2 (es) 2012-04-30
AP2011005700A0 (en) 2011-06-30
EP2529750A1 (fr) 2012-12-05
AR073957A1 (es) 2010-12-15
RU2011135761A (ru) 2013-03-10
RU2613295C2 (ru) 2017-03-15
RU2011120309A (ru) 2012-11-27
US20110195087A1 (en) 2011-08-11
EP2361094A4 (fr) 2012-12-05
WO2010046934A1 (fr) 2010-04-29
BRPI0920629A2 (pt) 2016-01-12

Similar Documents

Publication Publication Date Title
MA32821B1 (fr) Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)
ter Borg et al. Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: relation to treatment response
MY141025A (en) Dose forms
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2007130493A3 (fr) Combinaison adjuvante synergique d'anticorps agoniste cd40/interféron de type 1, conjugués contenant une telle combinaison et utilisation en tant qu'agent thérapeutique pour améliorer l'immunité cellulaire
WO2006072625A8 (fr) Procedes et traitements combines anti-kir
WO2007147001A3 (fr) Formulations lyophilisées d'anticorps anti-egfr
WO2008073448A3 (fr) Formulations pharmaceutiques et leurs procédés de production
UA88909C2 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение
WO2007047146A3 (fr) Inhibiteurs de réplication virale
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
WO2008014979A3 (fr) Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
WO2006126981A3 (fr) Compositions et methodes destinees a la vaccination par voie muqueuse
UA95238C2 (uk) Імуногенна композиція
WO2007057763A3 (fr) Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
MA30065B1 (fr) Vaccin
WO2007095976A3 (fr) Adjuvant sous forme d'acide nucléique modifié par un lipide
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
WO2007081896A3 (fr) Compositions pharmaceutiques et méthodes de vaccination contre les candidoses disséminées et d'autres agents infectieux
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
AP1891A (en) HIV immunogenic compositions and methods.
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
MX2010006984A (es) Vacunas contra la malaria.